XOMA (NASDAQ:XOMA) Stock Rating Upgraded by StockNews.com

XOMA (NASDAQ:XOMA) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $104.00 price target on shares of XOMA in a research note on Friday, March 28th.

XOMA Stock Performance

NASDAQ:XOMA opened at $19.97 on Friday. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The business’s 50-day moving average price is $22.14 and its two-hundred day moving average price is $26.20. The stock has a market cap of $238.70 million, a P/E ratio of -5.74 and a beta of 1.00. XOMA has a twelve month low of $18.35 and a twelve month high of $35.00.

XOMA (NASDAQ:XOMA) last released its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The company had revenue of $8.70 million during the quarter, compared to analysts’ expectations of $8.75 million. As a group, equities analysts predict that XOMA will post -1.41 EPS for the current fiscal year.

Insider Buying and Selling

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CIO Bradley Sitko purchased 4,134 shares of the stock in a transaction on Friday, March 21st. The shares were acquired at an average cost of $23.89 per share, with a total value of $98,761.26. Following the transaction, the executive now directly owns 10,484 shares in the company, valued at $250,462.76. The trade was a 65.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 29,312 shares of company stock worth $735,061 in the last 90 days. 7.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On XOMA

Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its position in XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares in the last quarter. State Street Corp boosted its stake in XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after purchasing an additional 1,754 shares in the last quarter. Barclays PLC grew its holdings in shares of XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 8,447 shares during the last quarter. Geode Capital Management LLC boosted its stake in XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after purchasing an additional 1,138 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in XOMA by 18.1% in the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock worth $291,000 after buying an additional 1,699 shares in the last quarter. Institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.